Preparation and Experimental Study of HER2-Targeted Dual-Mode Nanoprobes for Breast Cancer
GAO Xiaolong1, TIAN Hongda1, YIN Qiangqiang1, GU Hongqian1, YIN Huimin1, LIU Qiang1, LIU Li2
1. School of Medical Technology, Qiqihar Medical University, Qiqihar Heilongjiang 161006, China;
2. Imaging Center, The First Hospital of Qiqihar, Qiqihar Heilongjiang 161005, China
Abstract：Objective To construct a dual-mode nanoprobe Fe3O4-Cy5.5-trastuzumab with fluorescence imaging and magnetic
resonance imaging (MRI), and analyze its characterization, and to investigate the targeting and imaging of human epidermal growth
factor receptor 2 (HER2) -positive SKBR-3 cells in vitro. Methods Polyethyleneglycol (PEG) was added to superparamagnetic iron
oxide solution and pH was adjusted to 7.5 with NaHCO3 after centrifugation. The resulting solution was coupled to fluorescent Cy5.5
to obtain Fe3O4-PEG-trastuzumab. Then trastuzumab was added to the above solution and incubated overnight at room temperature,
and the unreacted trastuzumab was removed by centrifugation. The cytotoxicity was detected by CCK-8 method, the cell uptake
was measured by confocal laser scanning microscope, and its relaxation rate and enhancement were detected by Niumag small
NMR and MRI respectively. Results The prepared nanoprobe was observed by transmission electron microscope with uniform and
granular. Andits granularsize was (85.67±11.46) nm, hydration particle size was approximately (93.72±6.34) nm, the potential
was (-21.54±3.23) mV and the relaxation rate was 42.286mM-1s-1. MRI showed that the signal decreased as the probe concentration
increased. Fluorescence showed that red fluorescence was emitted at 690 nm excitation. Cytotoxicity showed that the probe was less
toxic. Conclusion HER2-targeted dual-mode probe Fe3O4-Cy5.5-trastuzumab is successfully synthesized and can specifically bind to
target cells in vitro.
高晓隆1，田洪达1，尹强强1，谷弘谦1，尹汇敏1，刘强1，刘力2. 以HER2为靶点的乳腺癌双模态纳米探针的制备与实验研究[J]. 中国医疗设备, 2022, 37(9): 142-145.
GAO Xiaolong1, TIAN Hongda1, YIN Qiangqiang1, GU Hongqian1, YIN Huimin1, LIU Qiang1, LIU Li2. Preparation and Experimental Study of HER2-Targeted Dual-Mode Nanoprobes for Breast Cancer. China Medical Devices, 2022, 37(9): 142-145.
